Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VLPCOV-02 (VLP Therapeutics)
- Development stage
- Preclinical
- Lead developer
- VLP Therapeutics Japan
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
VLPCOV-02 is a self-amplifying RNA (saRNA) vaccine candidate developed by VLP Therapeutics (also known as VLP The Vaccines Company) for the prevention of COVID-19. It is designed as a 'universal' vaccine intended to provide broad protection against multiple SARS-CoV-2 variants. The vaccine utilizes a lipid nanoparticle (LNP) delivery system to transport saRNA that encodes a redesigned receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, incorporating a pan-HLA-binding epitope to enhance immunogenicity. Additionally, the saRNA features a modified base, 5-methylcytosine, which is intended to reduce reactogenicity and improve the immune response. As of late 2025, the candidate is reported to be in the Preclinical/CMC stage of development for its universal application.
- Other names
- COVID-19 (Universal) vaccinesaRNA-LNP COVID-19 vaccine
02
Targets
SARS-CoV-2 conserved spike protein epitopes
Beyond the preview
Go deeper on VLPCOV-02 (VLP Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VLPCOV-02 (VLP Therapeutics).